

RECEIVED

NOV 22 2002

TECH CENTER 1600/2900

Express Mail No.: EL 451 598 986 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Baxter *et al.*

Confirmation No.: 7561

Application No.: 09/281,717

Group Art Unit: 1631

Filed: March 30, 1999

Examiner: M. Moran

For: METHODS AND COMPOUNDS FOR
MODULATING NUCLEAR RECEPTOR
COACTIVATOR BINDING

Attorney Docket No.: 9811-008-999

H27
Plunkett
11/24/02

REQUEST TO AMEND DRAWINGS UNDER 37 C.F.R. § 1.121(d)

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with Rule 121(d) of the Rules of Practice, Applicants hereby request permission to amend FIG. 7 in the above-identified patent application.

Applicants submit herewith a copy of FIG. 7, as originally filed, marked to indicate a proposed correction. As indicated in red ink on the copy of FIG. 7 as originally filed, Applicants propose to replace the heading, "NR-box1", of the middle column that denotes residues in SEQ ID NO: 6, with the heading "NR-box2".

This amendment is supported by the specification as filed at page 6, line 16 (paragraph [0027] of corresponding U.S. patent application publication 2002/0061539), in which can be found a brief description of FIG. 7 that refers to "NR-boxes 1, 2, and/or 3". Furthermore, the row-descriptions in FIG. 7 indicate which NR-box sequences are preserved in a series of mutations. It is clear that NR-box1 residues are present in all rows, whereas the NR-box2 sequence is only present in the first two rows. Thus, it would be clear to one of ordinary skill in the art that the sequences in column 2 of FIG. 7 are NR-box2 sequences and hence that the heading to the middle column of FIG. 7 as filed is an innocuous printing error. Accordingly this amendment to FIG. 7 does not introduce new matter, and entry thereof is respectfully requested.

In view of the foregoing, Applicants earnestly seek permission to submit an amended formal FIG. 7, upon the Examiner's approval of the attached amendment.

No fee is believed due with this Amendment. However, should the Commissioner determine otherwise, he is hereby authorized to charge any fees associated with this paper communication or credit any overpayment to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date November 18, 2002




Richard G. A. Bone (Reg. No.)

(Limited recognition under 37 C.F.R. § 10.9(b);
copy of certificate attached hereto.)

for Samuel B. Abrams (Reg. No. 30,605)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, NY 10036-2711

Enclosure



Express Mail No.: EL 451 598 986 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Baxter *et al.*

Confirmation No.: 7561

Application No.: 09/281,717

Group Art Unit: 1631

Filed: March 30, 1999

Examiner: M. Moran

For: METHODS AND COMPOUNDS FOR
MODULATING NUCLEAR RECEPTOR
COACTIVATOR BINDING

Attorney Docket No.: 9811-008-999

Amd to
clms entered
2/5/03
msy

Amor Docs
Correspond With
Spec.

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants have carefully considered the Office Action mailed July 17, 2002 in connection with the above-identified Application and request reconsideration of the claims in light of the amendments and remarks herein. Accompanying this Amendment are: (1) a Petition for Extension of Time, containing a provision for payment of the appropriate fee, extending the period for response by one month, to and including November 17, 2002; (2) marked up versions of paragraphs of the specification as filed, attached hereto as Appendix A; (3) marked up version of the amended claims attached hereto as Appendix B; (4) a copy of all pending Claims, after entry of this Amendment, attached hereto as Appendix C; and (5) a fee transmittal sheet.

AMENDMENT

In The Specification

Please amend the specification as follows. For the Examiner's convenience, reference is made to paragraph numbers in corresponding patent application publication U.S.

2002/0061539 A1, published May 23, 2002.

11/21/2002 YPOLITE1 00000040 161150 09281717

01 FC:1202 216.00 CH